(City Name, China, Date: 17/7/205) – Huarong Pharma, a well-known domestic pharmaceutical enterprise, officially announced today that it has signed a strategic cooperation agreement with Laos Alliance Pharmaceutical Group, a leading pharmaceutical company in Laos. The two parties will jointly invest 30 million yuan to build a 1,000-square-meter modern active pharmaceutical ingredient (API) production workshop within Alliance's existing industrial park. This workshop will adhere to dual standards of China GMP and ASEAN GMP. Huarong Pharma will provide full-process core technology transfer, marking a new phase of its international expansion shifting from "cooperation" to "physical operation."
As a benchmark in Laos' pharmaceutical industry, Laos Alliance Pharmaceutical Group was founded by Chongqing entrepreneur Chen Ting and has operated locally for 28 years with a robust industrial foundation. The company boasts a sales network covering over 90% of medical institutions in Laos, mature ASEAN drug registration and customs clearance capabilities, and a 7.3-hectare industrial park with WHO pre-certified workshops . Leveraging Laos' generic drug policy advantages and logistics from the China-Laos Railway, Alliance has secured a 27% market share as a leading pharmaceutical enterprise in Laos .
This collaboration emphasizes "technology empowerment + resource integration": Huarong Pharma will lead core technology transfer, including API production processes, quality control systems, and production line optimization for cardiovascular and anti-infective drugs, ensuring products meet high-end international standards. Alliance will handle local site renovations, workforce training, and Southeast Asian market channel development, facilitating rapid market access across Laos, Thailand, Vietnam, and other ASEAN nations . Upon completion, the workshop will achieve an annual capacity of 370 tons, supplementing Southeast Asia's high-demand API supply and strengthening regional pharmaceutical supply chain stability .
Song Jiang, General Manager of Huarong Pharma, stated: "The 30 million yuan investment and technology transfer demonstrate Huarong's commitment to Southeast Asia. With our patented API process R&D and Alliance's local resources, the 1,000-square-meter facility and 370-ton capacity will enable construction to start in October 2025 and production in early 2026. We aim to establish a pragmatic platform for Chinese pharmaceutical technology to globalize, supporting our Southeast Asian market expansion."
Chen Ting, Founder of Laos Alliance Pharmaceutical Group, highlighted: "Huarong's technology transfer fills Laos' high-end API production gap. Previously reliant on Chinese imports, this project will rapidly achieve independent supply of key raw materials, reducing import dependency and enhancing our industrial chain. Future plans include expanding into formulation processing and joint R&D to explore a 'raw material-finished product' collaborative model."
Scheduled for groundbreaking in October 2025 and production launch in early 2026, the API workshop will become Huarong Pharma's first physical production base in Southeast Asia, laying groundwork for further global market penetration .
About Huarong Pharma
Huarong Pharma is a comprehensive pharmaceutical enterprise specializing in R&D and production of chemical APIs and intermediates. With 3 national-level high-tech products and core patents, it excels in green synthesis and process optimization, exporting to over 20 countries/regions including Europe, the U.S., Japan, and South Korea. Committed to "compliant production and innovation-driven development," the company delivers high-quality products and technical services globally.
About Laos Alliance Pharmaceutical Group
Founded in 1995 by Chen Ting, Laos Alliance Pharmaceutical Group is Laos' first ASEAN GMP-certified pharmaceutical enterprise. Its operations covers API import, formulation production, and medical device sales across a 7.3-hectare industrial park. Leveraging Laos' pharmaceutical IP exemption policies and China-Laos Railway logistics, its anti-infective and chronic disease treatments dominate Laos' market. As a designated public health emergency drug reserve unit, it holds a 27% market share .